Latest News

šŸ“Œ Let's meet in San Diego (USA) - April 5-9, 2025 - booth #2043 Our team will be delighted to welcome you at the AAN 2025 Annual Meeting, "The best and largest gathering for neurologists and neuroscience professionals"! This year, we'll be exhibiting at booth #2043 where you'll discover our relevant & translatable in vitro and in vivo solutions for neurology & neurovascular disorders. šŸ§  You'll learn more about Brain-on-Chip for PoC on your targets, models of proteinopathies & other neuronal injuries, our

šŸ“Œ See you in Vienna (Austria) - from 1st to 5th April 2025! We are participating in the 40th AD/PD 2025 as a preclinical CRO expert in AD's and PD's disease research . šŸ“… Stop by our booth #25 Alzheimerā€™s & Parkinsonā€™s Diseases Conference is a leading event in the field of neurodegenerative diseases and this year we are exhibiting on booth #25 to present our in vitro & in vivo services dedicated to AD's & PD's translational neuroscience, especially focused on proteinopathies

Brain-on-chips (BoC) are innovative tools that simulate complex brain environments, enhancing our understanding of neurodegenerative diseases (NDDs). While a range of BoC platforms have been developed to model diverse NDD pathophysiologies, the various channel architectures of these microfluidic devices present challenges in image acquisition and analysis. High-content imaging protocols must be adaptable to these differing designs.   This Technical Note, developed by Revvity in collaboration with ETAP-Lab, demonstrates an automated image acquisition protocol for BoC microfluidic devices. The protocol utilizes the Operetta

Cardiovascular diseases (CVDs) are the leading cause of global mortality. That's why we are proud to share a groundbreaking study titled "Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers". Liu, Sophia et al. iScience, Volume 28, Issue 2, 111814   This study highlights the potential of Urolithin A (UA), a post-biotic and mitophagy activator, to improve heart health by addressing mitochondrial dysfunctions. Preclinical model results show reduced cardiac dysfunction, while human trials indicate significant reductions

We are thrilled to announce our participation in the 13th Alzheimerā€™s & Parkinsonā€™s Drug Development Summit as a solution provider and preclinical CRO expert in AD's and PD's disease studies. This summit is a unique opportunity to unite new faces across biotech and pharma, capitalize on groundbreaking progress, and accelerate the development of transformative neurodegenerative therapies. šŸ“… If you're attending the conference, book a meeting with JĆ©rome BERNARD who will be in Boston all the week by clicking here. Let'discover ETAP-Lab's dedicated

We wanted to highlight on our recent article on our psychopharmacology research "The Anxiolytic-like Properties of a Tryptic Hydrolysate of Bovine Ī±s1 Casein Containing Ī±-Casozepine Rely on GABAA Receptor Benzodiazepine Binding Sites but Not the Vagus Nerve" that has reached over 3000 views in MDPI Nutrients journal!   The published data on the anxiolytic-like properties of bovine Ī±s1-casein (CH) support that: Ī±-casozepine is responsive for the anxiolytic-like effects of the alpha-s1-casein tryptic hydrolysate (CH). CH anxiolytic-like effects are not mediated by the

šŸŽ„ Today we're sharing a documentary about Parkinson's on the famous French program "Health Investigation: Our Lives with Parkinson's" Parkinson's disease is the second leading cause of motor disability in adults after strokes, with 25,000 new cases each year in France. To date, there is no cure for this complex disorder, so research continues !   šŸ§  In this documentary, journalist and producer Joseph Coriat, diagnosed at 38, shares his experience and meets with 6 persons to talk about daily life with

šŸ“ŒETAP-Lab is delighted to present for the first time a poster at the American Heart Associationā€™s annual International Stroke Conference 2025, in Los Angeles, CA from February 5 to 7, 2025. As a leading international conference in cerebrovascular disease and brain health, the AHA's International Stroke Conference was the ideal platform to highlight our preclinical stroke research expertise.   ETAP-Lab, preclinical efficacy CRO, will be presenting its poster on original preclinical results about in vivo trials on Stroke disease.   šŸ“…Meet our expert during the

Our mission is to contribute to the development of molecules and therapies for our customers in the field of human health. But that doesn't stop us from being amazed by the beauty of biology.   When art and biology meet, it results in #FluorescenceFriday!   We regularly share our most beautiful images, and love to look curiously at the publications of other passionate scientists. Join us by following the hashtag #FluorescenceFriday on LinkedIn if you're eager to be amazed, to have glitter in your eyes while

As we look back over the past year and forward to the future, we are grateful to our valued customers and partners, and the trust they place in us is our greatest gift. šŸŽ But without our employees, nothing would be possible. That's why we thank everyone at ETAP-Lab, STROK@lliance and SYNCROSOME.Ā We appreciate their dedication, passion and positive attitude on every day. With our teams growing, we're convinced that this new year will be a great one ! We look forward to